Exosomics is a company located in Siena (Italy), founded in 2011 with the aim to leverage the EV potential for diagnostic purposes. Currently Exosomics provides a range of pre-analytical solutions able to enrich tumor-derived EVs and exosomes from human biofluids and extract their genomic DNA and RNA content. This technology allows earlier detection of tumor-causing mutations from liquid biopsies and enables the next generation of cancer screening, staging, profiling and monitoring tests.
Our technologies are efficient in both biomarker discovery and confirmation studies, and comply with clinical grade analytical platforms. Additionally, they are open platform for customizable solutions suitable for discovery of disease-associated biomarkers.
In 2019, Exosomics acquired HansaBioMed Life Sciences a company entirely focused on the research in the field of exosomes, extracellular vesicles (EVs) and nanoparticles.
In 2024 Exosomics established LongEVity Bioscience to address the cosmetic and nutraceutical markets with plant EVs as potent active ingredients.
Our expertise in the field has attracted some major Pharma/Biotech and Cosmetic companies who have entrusted us with their studies about EVs.
Company Details
- Founded
- -
- Address
- Siena, Tuscany 53100, It
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.exosomics.it/
- Keywords
- Liquid biopsy, Cancer Screening, Circulating extracellular vesicles, selective tumor originated exosome isolation and enrichment, exosome tumor-associated biomarkers, Diagnostics, Cosmetics, Nutraceutical, Services, loading EVs, EV isolation, EV characterization, Decorating EVs.
- HQ
- Siena, Tuscany
Exosomics Spa Questions
Exosomics Spa's website is http://www.exosomics.it/
Exosomics Spa's LinkedIn profile is https://it.linkedin.com/company/exosomics
Exosomics Spa's industry is
Biotechnology Research
Exosomics Spa's categories are Biotechnology Research
Exosomics Spa's founding year is 2011
